Deficits in passive avoidance learning in young rats following mecamylamine injections in the hippocampo-entorhinal area
暂无分享,去创建一个
[1] A. Cudennec,et al. Deficits in passive-avoidance learning following atropine in the developing rat , 1977, Psychopharmacology.
[2] D. Blozovski,et al. Effects of antimuscarinic cholinergic drugs injected systemically or into the hippocampo-entorhinal area upon passive avoidance learning in young rats , 2004, Psychopharmacology.
[3] A. Cudennec,et al. Passive avoidence learning in the young rat. , 1980, Developmental psychobiology.
[4] B. Campbell,et al. Ontogeny of passive avoidance: role of task demands and development of species-typical behaviors. , 1980, Developmental psychobiology.
[5] D. Blozovski. PA-learning in young rats with dorsal hippocampal- and hippocampo-entorhinal atropine , 1979, Pharmacology Biochemistry and Behavior.
[6] M. Segal. The acetylcholine receptor in the rat hippocampus; nicotinic, muscarinic or both? , 1978, Neuropharmacology.
[7] Y. Dudai,et al. Distribution of an α-bungarotoxin-binding cholinergic nicotinic receptor in rat brain , 1978, Brain Research.
[8] I. Whishaw,et al. Postnatal hippocampal granule cell agenesis in the rat: effects on two types of rhythmical slow activity (RSA) in two hippocampal generators , 1978, Brain Research.
[9] D. Ray,et al. Emerging cholinergic mechanisms and ontogeny of response inhibition in the mouse. , 1978, Journal of comparative and physiological psychology.
[10] R. Bradley,et al. Regional distribution of nicotinic acetylcholine receptor in rat brain , 1977, Brain Research.
[11] D. Riccio,et al. Scopolamine's effect on passive avoidance behavior in immature rats. , 1976, Developmental psychobiology.
[12] G. Aghajanian,et al. The cholinergic pharmacology of hippocampal pyramidal cells: A microiontophoretic study , 1976, Neuropharmacology.
[13] H. Karten,et al. Autoradiographic localisation of α-bungarotoxin-binding sites in the central nervous system , 1975, Nature.
[14] W. Moore,et al. Subcellular and regional distribution of 125I-labeled alpha-bungarotoxin binding in rat brain and its relationship to acetylcholinesterase and choline acetyltransferase. , 1975, The Journal of biological chemistry.
[15] S. H. Snyder,et al. In vivo identification of muscarinic cholinergic receptor binding in rat brain. , 1974, Brain research.
[16] D. A. Feigley. Effects of scopolamine on activity and passive avoidance learning in rats of different ages. , 1974, Journal of comparative and physiological psychology.
[17] S. P. Grossman,et al. Intrahippocampal application of cholinergic agents and blockers: effects on rats in differential reinforcement of low rates and Sidman avoidance paradigms. , 1974, Journal of comparative and physiological psychology.
[18] A. McComas,et al. A stereotaxic atlas of the developing rat brain , 1972 .
[19] P. Livesey,et al. Age effects in the acquisition and retention of active and passive avoidance learning by rats. , 1972, Developmental psychobiology.
[20] D. Riccio,et al. Acquisition and retention of a passive-avoidance response as a function of age in rats. , 1971, Journal of comparative and physiological psychology.
[21] P. L. Carlton,et al. 7 – Behavioral Effects of Atropine and Scopolamine1 , 1971 .
[22] E. Furchtgott. Pharmacological and biophysical agents and behavior , 1971 .
[23] N. Spear,et al. Effect of age and punishment condition on long-term retention by the rat of active- and passive-avoidance learning. , 1970, Journal of comparative and physiological psychology.
[24] D. Riccio,et al. Age-related deficits in acquisition of a passive aviodance response. , 1969, Canadian journal of psychology.
[25] M. Rohrbaugh,et al. Developmental aspects of passive and active avoidance learning in rats , 1968 .
[26] K. Koketsu,et al. Effects of Mecamylamine on the Golgi Recurrent Collateral-Renshaw-Cell Synapse in the Spinal Cord , 1961 .
[27] C. A. Stone,et al. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine. , 1956, The Journal of pharmacology and experimental therapeutics.